California lab and its owner agree to pay $1.25 million to resolve allegations of kickbacks to marketers
Published November 8, 2026 · Coverage November 1–7, 2026, Pacific · Medium priority
DOJ's Civil Division and the U.S. Attorney's Office for the Eastern District of California announced on November 6 that Lab Genomics LLC, a Fountain Valley, California clinical laboratory, and its owner Leena Dalal agreed to pay $1,250,000 to resolve False Claims Act allegations. The United States alleged that from January 2020 through September 2022 Lab Genomics and Dalal knowingly and willfully paid value- and volume-based commissions to three independent contractor marketers to induce them to arrange for or recommend that providers order lab tests, and structured invoices so the commissions looked like flat fees. The matter came from a qui tam suit; the relators will receive $225,000. The settlement agreement states $625,000 of the amount is restitution and that the agreement is neither an admission of liability by the laboratory and its owner nor a concession by the United States that its claims are not well founded. DOJ states the claims are allegations only and there has been no determination of liability. No Corporate Integrity Agreement is mentioned.
Background
The Anti-Kickback Statute prohibits offering, paying, soliciting or receiving remuneration to induce referrals of items or services covered by Medicare, Medicaid and other federally funded health care programs, and claims knowingly submitted in violation of it can violate the False Claims Act. The case began as a lawsuit filed by two private parties under the False Claims Act's whistleblower provisions, and the United States previously resolved similar allegations against Admera Health LLC and another company.
Who this affects
Clinical laboratories, hospital outreach laboratories, and any provider that pays independent-contractor marketers or sales agents to generate orders or referrals for federally reimbursed services.
Why it matters
Inference: arrangements that pay outside marketers or sales contractors per test, per referral or as a share of revenue for federally reimbursed services carry Anti-Kickback Statute exposure, and the government alleged that invoices were structured to make volume-based commissions appear to be flat fees. Hospitals with outreach laboratory programs or marketing vendors should be able to show how each contractor is paid.
Required actions
- None for organizations that are not parties to this settlement. The payment obligation falls on the laboratory and its owner.
Recommended action
- Inventory contracts with independent marketers, sales agents and lead-generation vendors tied to laboratory or other federally reimbursed services, and confirm none pays by volume or value of referrals.
- Compare invoices against contract compensation terms to detect flat-fee invoices that mask variable commissions.
- Confirm legal review of any marketer arrangement under the Anti-Kickback Statute.
Scope and timing
- Authority status
- Settled
- Responsible owner
- Compliance; Legal; Laboratory leadership
- Publication date
- 2026-11-06
- Other dates
- Settlement agreement signature dates shown as 10/30/2026 (two signature blocks; the date of a third is not established). Alleged conduct period January 2020 through September 2022.
Not established
The release caption (v. Admera Health, LLC, et al.) and the agreement caption (v. Lab Genomics, LLC et al., No 2:19-cv-01288-JAM-JDP, with a complaint filed November 9, 2020) differ; both are as stated in their documents.
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Enforcement Briefing report →